{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:10:04Z","timestamp":1792509004256,"version":"4.5.0"},"reference-count":55,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Midwife Womens Health"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteoporosis is described as a silent disease prior to fracture, and the sequelae of an osteoporotic fracture can be devastating. Primary care providers should routinely assess and remediate bone health during wellness visits for women aged at least 50 years. Assessment includes review of a variety of risk factors, bone density testing, and an online fracture risk assessment tool calculation. Diagnosis is based on bone density score and clinical risk factors. Evidence\u2010based nonpharmacologic therapies are important adjuncts of care, and pharmacologic intervention may also be recommended. A variety of pharmacologic options are available for women with postmenopausal osteoporosis, and it is important to weigh benefits and risks. Pharmacologic indications, therapeutic variations among products, adverse effect profiles, administration considerations, and cost are addressed. Once pharmacotherapy is initiated, duration and drug holidays should also be considered. In general, medication benefits fade when treatment stops, so health care providers should be prepared to routinely revisit therapy indicators that will help define risk and guide treatment decisions. A comprehensive approach to bone health can make a valuable difference in the health of women.<\/jats:p>","DOI":"10.1111\/jmwh.12954","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T13:44:52Z","timestamp":1552571092000},"page":"265-275","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Clinical Update on Osteoporosis"],"prefix":"10.1111","volume":"64","author":[{"given":"Angelina","family":"Anthamatten","sequence":"first","affiliation":[{"name":"Vanderbilt University School of Nursing  Nashville TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Parish","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Nursing  Nashville TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161435.ESGL"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glt093"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2794-2"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2269"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.6.785"},{"key":"e_1_2_10_7_1","volume-title":"The Surgeon General's Report on Bone Health and Osteoporosis: What It Means to You","author":"Office of the Surgeon General, US Department of Health and Human Services","year":"2015"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.09.011"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.061113"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1361"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.06.006"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3347"},{"key":"e_1_2_10_13_1","volume-title":"FRAX: Fracture Risk Assessment Tool","author":"Centre for Metabolic Diseases, University of Sheffield","year":"2016"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-011-1863-5"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X14546350"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12018-015-9190-0"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001124"},{"key":"e_1_2_10_18_1","volume-title":"A Guide to Drug Safety Terms at FDA","author":"US Food and Drug Administration","year":"2012"},{"key":"e_1_2_10_19_1","volume-title":"Epocrates [mobile app]","year":"2018"},{"key":"e_1_2_10_20_1","volume-title":"Depo\u2010Provera (medroxyprogesterone acetate) injectable suspension [package insert]","year":"2010"},{"key":"e_1_2_10_21_1","volume-title":"Technical Consultation on the Effects of Hormonal Contraception on Bone Health. Summary Report Geneva, Switzerland, 20\u201021 June, 2005","author":"World Health Organization","year":"2007"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000450758.95422.c8"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107142"},{"key":"e_1_2_10_24_1","volume-title":"National Osteoporosis Foundation (NOF)\/International Society for Clinical Densitometry (ISCD) FRAX Implementation Guide","author":"National Osteoporosis Foundation and International Society for Clinical Densitometry","year":"2009"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4580"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijge.2014.06.001"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4183"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3386-5"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.19344"},{"key":"e_1_2_10_30_1","volume-title":"GoodRx [mobile app]","year":"2018"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2405"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0317"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/215034"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2011.0108"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1998"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1893"},{"key":"e_1_2_10_37_1","volume-title":"Osteoporosis Treatment Decision Tool","author":"American Association of Clinical Endocrinologists; American College of Endocrinology"},{"key":"e_1_2_10_38_1","volume-title":"Prolia (denosumab) [package insert]","year":"2018"},{"key":"e_1_2_10_39_1","unstructured":"Risk Evaluation and Mitigation Strategies (REMS).US Food and Drug Administration website.https:\/\/www.fda.gov\/Drugs\/DrugSafety\/REMS\/default.htm. Updated February 2 2018. Accessed November 19 2018."},{"key":"e_1_2_10_40_1","unstructured":"Approved Risk Evaluation and Mitigation Strategies(REMS): Prolia (denosumab). US Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm?event=IndvRemsDetails.page&REMS=43. Updated May 21 2015. Accessed October 23 2018."},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-018-0464-6"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.08.003"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/bonekey.2014.13"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.2217\/17455057.4.3.257"},{"key":"e_1_2_10_45_1","volume-title":"Premarin (conjugated estrogens tablets, USP) [package insert]","year":"2011"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000921"},{"issue":"3","key":"e_1_2_10_47_1","first-page":"178","article-title":"Conjugated estrogens\/bazedoxifene (Duavee): a novel agent for the treatment of moderate\u2010to\u2010severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis","volume":"40","author":"Goldberg T","year":"2015","journal-title":"P T"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1676-0"},{"key":"e_1_2_10_49_1","volume-title":"Miacalcin (calcitonin\u2010salmon) nasal spray [package insert]","year":"2017"},{"key":"e_1_2_10_50_1","unstructured":"Questions and answers: changes to the indicated population for Miacalcin (calcitonin\u2010salmon). US Food and Drug Administration website.https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm388641.htm. Updated September 1 2015. Accessed October 23 2018."},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3339-z"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005496"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.04.007"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050336"},{"issue":"1523","key":"e_1_2_10_55_1","first-page":"e104","article-title":"Comparison table: some drugs for postmenopausal osteoporosis","volume":"59","year":"2017","journal-title":"Medical Lett Drugs Ther"},{"key":"e_1_2_10_56_1","unstructured":"Osteoporosis medications. GoodRx website.https:\/\/www.goodrx.com\/osteoporosis\/drugs. Accessed October 23 2018."}],"container-title":["Journal of Midwifery &amp; Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjmwh.12954","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jmwh.12954","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jmwh.12954","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jmwh.12954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T20:24:16Z","timestamp":1694377456000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jmwh.12954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/jmwh.12954"],"URL":"https:\/\/doi.org\/10.1111\/jmwh.12954","archive":["Portico"],"relation":{},"ISSN":["1526-9523","1542-2011"],"issn-type":[{"value":"1526-9523","type":"print"},{"value":"1542-2011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"2018-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}